The company said its officers will reaffirm the company's shareholders' earnings guidance for full year 2025 to be $30.40 to $31.10 per diluted share during investor meetings, including approximately $3.75 per diluted share of net unfavorable items.

1. 01

   The company said its officers will reaffirm the company's shareholders' earnings guidance for full year 2025 to be $30.40 to $31.10 per diluted share during investor meetings, including approximately $3.75 per diluted share of net unfavorable items.

2. 02

   The company said it continues to expect adjusted shareholders' earnings, excluding net unfavorable items, to be $34.15 to $34.85 per diluted share.

3. 03

   The company said it continues to expect year-end 2025 total medical enrollment to be consistent with the guidance it provided in its earnings release dated January 23, 2025 for Q4 2024, and it expects Medicare Advantage membership of 2.2 to 2.25 million members.

4. 04

   Elevance Health said its officers will speak with investors over the next several weeks, and that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.